JMackem Co., Ltd
🇰🇷South Korea
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Oral Administration of AJH-2947 in Healthy Korean and/or Caucasian Adult Male Subjects
Phase 1
- Conditions
- Neuropathic PainPost Herpetic NeuralgiaDiabetic Neuropathies
- Interventions
- Drug: AJH-2947 400 mg (SAD)Drug: AJH-2947 300 mg (SAD)Drug: AJH-2947 400 mg (MAD)Drug: AJH-2947 200 mg (SAD)Drug: AJH-2947 100 mg (SAD)Drug: AJH-2947 800 mg (SAD)Drug: AJH-2947 200 mg (MAD)Drug: AJH-2947 600 mg (SAD)Drug: AJH-2947 600 mg (MAD)Drug: Placebo
- First Posted Date
- 2023-12-04
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- JMackem Co., Ltd
- Target Recruit Count
- 68
- Registration Number
- NCT06155487
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
News
No news found